Where does J&J's new drug fit in the crowded HIV market?

Johnson & Johnson's research unit Janssen Pharmaceuticals said Tuesday that U.S. regulators approved the once-daily medicine Symtuza for adult HIV patients who are either treatment-naive or virologically suppressed on a stable antiretroviral regimen. Symtuza carries a black box warning for post-treatment acute exacerbation of hepatitis B — an oft-cited caution with HIV drugs.